Edwards Lifesciences Corp (EW)
Pretax margin
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 1,588,900 | 1,620,500 | 1,657,000 | 1,608,900 | 1,598,100 | 1,635,700 | 1,603,700 | 1,729,900 | 1,767,400 | 1,684,400 | 1,668,000 | 1,748,800 | 1,702,000 | 1,681,800 | 1,655,200 | 941,500 | 916,700 | 876,100 | 813,500 | 1,253,000 |
| Revenue (ttm) | US$ in thousands | 5,724,300 | 5,872,600 | 5,999,100 | 6,143,400 | 6,004,800 | 5,819,000 | 5,657,100 | 5,500,800 | 5,382,400 | 5,363,800 | 5,355,000 | 5,357,100 | 5,232,500 | 5,094,500 | 4,925,200 | 4,474,200 | 4,386,300 | 4,368,700 | 4,321,800 | 4,483,700 |
| Pretax margin | 27.76% | 27.59% | 27.62% | 26.19% | 26.61% | 28.11% | 28.35% | 31.45% | 32.84% | 31.40% | 31.15% | 32.64% | 32.53% | 33.01% | 33.61% | 21.04% | 20.90% | 20.05% | 18.82% | 27.95% |
December 31, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $1,588,900K ÷ $5,724,300K
= 27.76%
The pretax margin of Edwards Lifesciences Corp has displayed fluctuating trends over the analyzed period from March 31, 2020, to December 31, 2024. Starting at 27.95% in March 2020, the pretax margin decreased to 18.82% by June 2020, indicating a decrease in profitability before accounting for taxes.
The margin improved steadily from June 2020 to March 2021, reaching 21.04%. Subsequently, there was a significant increase in profitability, with the pretax margin peaking at 33.61% by June 2021, and remaining above 30% until September 2022. This period reflects a strong performance in generating income before taxes relative to revenue.
From September 2022, the pretax margin showed a slight decline, ranging between 28% to 32% up to December 2024. The company managed to maintain relatively high profitability levels during this period, indicating efficient cost management and revenue generation capabilities.
Overall, the pretax margin analysis indicates varying levels of profitability for Edwards Lifesciences Corp, with some periods of significant improvement and stability, interspersed with slight declines. Continued monitoring of the pretax margin will be essential to assess the company's ongoing financial performance and competitiveness in the market.
Peer comparison
Dec 31, 2024